RxDoctor Payments Data

Kenda Dean

Family · Grandfield, OKNPI 1801081658

Payments from drug & device makers

$177in general payments, 2019–2025

Across 9 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ANI Pharmaceuticals, Inc.$69
  • Ultragenyx Pharmaceutical Inc.$28
  • Xeris Pharmaceuticals, Inc.$20
  • Lilly USA, LLC$17
  • GSK$16
  • Sanofi-aventis U.S. LLC$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$177 in reported general payments places this provider in the 35th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$62,878
Medicare patients
145
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide104$103,273
OzempicSemaglutide96$95,325
MounjaroTirzepatide58$70,321
EliquisApixaban83$68,261
JardianceEmpagliflozin98$68,187
Dupixent PenDupilumab14$54,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$45,549
Tresiba Flextouch U-200Insulin Degludec43$41,823
XareltoRivaroxaban29$27,675
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$20,652
VraylarCariprazine Hcl13$19,207
LinzessLinaclotide27$18,862
Synjardy XrEmpagliflozin/Metformin Hcl27$17,812
Advair HfaFluticasone Propion/Salmeterol25$14,426
JanumetSitagliptin Phos/Metformin Hcl14$13,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$173,594162 claims
GSKTrelegy Ellipta, Incruse Ellipta$16$50,55578 claims
AbbVieVraylar, Linzess$13$38,06940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,026 family providers in Oklahoma.

Other family in Grandfield

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →